AmpliPhi Biosciences (NYSE American: APHB) is a clinical-stage biotechnology company focused on the development of bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. Antibiotic resistance is a major global challenge to human health as the incidence of antibiotic-resistant infections continues to increase, resulting in seemingly harmless infections causing serious morbidity or even death.
A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child’s scratched knee could once again kill.
Phages. Natural Born Killers of Pathogenic Bacteria.
Bacteriophages, or more simply “phages,” are the natural predators of bacteria and are thought to be the most abundant life form on earth. Phages have evolved an incredible diversity of strains that typically prey upon just a few closely related strains or species of bacteria. This enables phage therapies to precisely target pathogenic bacteria without harming the beneficial microbiota. Phages can infect and kill bacteria, whether antibiotic-resistant or not, and even if they have formed protective biofilms.
A Precise and Powerful Approach. Meeting The Challenge of Antibiotic Resistance.
We believe that phage therapeutics are uniquely positioned to address the serious threat of antibiotic-resistance. They can be precisely targeted to kill select bacteria, have a mechanism of action distinct from those of antibiotics, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics, and have been shown to restore antibiotic sensitivity to drug-resistant bacteria.